HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Patients with de novo AML enrolled in the study. Patient who has a HLA-identical donor is
assigned to receive NST therapy with GVHD prophylaxis and who has no HLA-identical donor is
assigned to receive MST therapy without GVHD prophylaxis.
Phase:
Phase 3
Details
Lead Sponsor:
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences